Multicentre, controlled, prospective, randomized, open-label clinical trial to compare enteric-coated mycophenolate sodium (EC-MPS) plus reduced dose cyclosporine microemulsion (CsA-ME) vs EC-MPS plus standard dose CsA-ME in elderly de novo renal transplant recipients treated with basiliximab and short-term steroids.

Trial Profile

Multicentre, controlled, prospective, randomized, open-label clinical trial to compare enteric-coated mycophenolate sodium (EC-MPS) plus reduced dose cyclosporine microemulsion (CsA-ME) vs EC-MPS plus standard dose CsA-ME in elderly de novo renal transplant recipients treated with basiliximab and short-term steroids.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2011

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Basiliximab; Ciclosporin; Corticosteroids
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 17 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top